Mefloquine neurotoxicity and gap junction blockade: Critical insights in drug repositioning

NeuroToxicology

Volumn 32, Issue 6, 2011, Pages 986-987

  Nevin, Remington L ^a  

^a Bayne Jones Army Community Hospital   (United States)

Author keywords

Connexin 36; Gap junction; Mefloquine; Neurotoxicity; Psychoactive

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CONNEXIN 36; MEFLOQUINE;

AMYGDALOID NUCLEUS; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; DOPAMINERGIC ACTIVITY; DRUG CHOICE; DRUG INDICATION; DRUG REPOSITIONING; DRUG TOLERABILITY; ELECTRICAL SYNAPSE; GLIOBLASTOMA; HEALTH CARE POLICY; HUMAN; LETTER; LEUKOENCEPHALOPATHY; LUNG HYDATID CYST; MEDICAL RESEARCH; NEUROPHARMACOLOGY; NEUROTOXICITY; PLASMODIUM MALARIAE INFECTION; PREVALENCE; PRIORITY JOURNAL; SCHISTOSOMIASIS; SEIZURE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VENTRAL TEGMENTUM; WORLD HEALTH ORGANIZATION;

ANIMALS; CEREBRAL CORTEX; MEFLOQUINE; TYK2 KINASE;

EID: 80055064853     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.05.003     Document Type: Letter

References (22)

1. Allison DW, Wilcox RS, Ellefsen KL, Askew CE, Hansen DM, Wilcox JD, et al. Mefloquine effects on ventral tegmental area dopamine and GABA neuron inhibition: a physiologic role for connexin-36 gap junctions. Synapse; in press, doi:10.1002/syn.20917.
2. Bissiere S., Zelikowsky M., Ponnusamy R., Jacobs N.S., Blair H.T., Fanselow M.S. Electrical synapses control hippocampal contributions to fear learning and memory. Science 2011, 331:87-91.
3. Chung L., Moore S.D. Neuropeptides modulate compound postsynaptic potentials in basolateral amygdala. Neuroscience 2009, 164:1389-1397.
4. Croft A.M. A lesson learnt: the rise and fall of Lariam and Halfan. J R Soc Med 2007, 100:170-174.
5. Department of Defense. Office of the Assistant Secretary of Defense for Health Affairs. Policy Memorandum on the Use of Mefloquine (Lariam®) in Malaria Prophylaxis. September 4; 2009. Accessed February 5; 2011. http://www.health.mil/libraries/HA_Policies_and_Guidelines/09-017.pdf.
6. Focosi D., Marco T., Kast R.E., Maggi F., Ceccherini-Nelli L., Petrini M. Progressive multifocal leukoencephalopathy: what's new?. Neuroscientist 2010, 16:308-323.
7. Geng Y., Kohli L., Klocke B.J., Roth K.A. Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010, 12:473-481.
8. Hood J.E., Jenkins J.W., Milatovic D., Rongzhu L., Aschner M. Mefloquine induces oxidative stress and neurodegeneration in primary rat cortical neurons. Neurotoxicology 2010, 31:518-523.
9. Juszczak G.R., Swiergiel A.H. Properties of gap junction blockers and their behavioural, cognitive and electrophysiological effects: animal and human studies. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:181-198.
10. Keiser J., N'Guessan N.A., Adoubryn K.D., Silué K.D., Vounatsou P., Hatz C., et al. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 2010, 50:1205-1213.
11. Küster T., Stadelmann B., Hermann C., Scholl S., Keiser J., Hemphill A. In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis. Antimicrob Agents Chemother 2011, 55:713-721.
12. Milatovic D, Jenkins JW, Hood JE, Yu Y, Rongzhu L, Aschner M. Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase. Neurotoxicology; in press, doi:10.1016/j.neuro.2011.01.001.
13. Nevin R.L. Mefloquine prescriptions in the presence of contraindications: prevalence among US military personnel deployed to Afghanistan, 2007. Pharmacoepidemiol Drug Saf 2010, 19:206-210.
14. Potasman I., Beny A., Seligmann H. Neuropsychiatric problems in 2,500 long-term young travellers to the tropics. J Travel Med 2000, 7:5-9.
15. Sánchez J.L., DeFraites R.F., Sharp T.W., Hanson R.K. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 1993, 341:1021-1022.
16. Schlagenhauf P., Adamcova M., Regep L., Schaerer M.T., Rhein H.G. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010, 9:357.
17. Steffensen SC, Bradley KD, Hansen DM, Wilcox JD, Wilcox RS, Allison DW, et al. The role of connexin-36 gap junctions in alcohol intoxication and consumption. Synapse; in press, doi:10.1002/syn.20885.
18. Strauch S., Jantratid E., Dressman J.B., Junginger H.E., Kopp S., Midha K.K., et al. Biowaiver monographs for immediate release solid oral dosage forms: mefloquine hydrochloride. J Pharm Sci 2011, 100:11-21.
19. Toovey S. Mefloquine neurotoxicity: a literature review. Travel Med Infect Dis 2009, 7:2-6.
20. Van essen T.A., Van der giessen R.S., Koekkoek S., Werf F.V., De zeeuw C.I., Van genderen P.J., et al. Anti-malaria drug mefloquine induces motor learning deficits in humans. Front Neurosci 2010, 4:191.
21. Voss L.J., Jacobson G., Sleigh J.W., Steyn-Ross A., Steyn-Ross M. Excitatory effects of gap junction blockers on cerebral cortex seizure-like activity in rats and mice. Epilepsia 2009, 50:1971-1978.
22. World Health Organization Guidelines for the Treatment of Malaria 2010, Accessed February 5; 2011. http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf, 2nd ed.